Treatment with the FLT3-targeted therapeutic gilteritinib (Xospata) improved survival for
Pfizer and Lilly Announce Top-line Results From Phase 3 Study of Tanezumab in Chronic Low Back Pain
February 19, 2019 — Pfizer Inc. (NYSE: PFE) and Eli
Persistent, prolonged opioid use occurs after plastic surgery
(HealthDay)—Persistent and prolonged opioid use occur after plastic and reconstructive
Why a common antibiotic treating diarrhea is failing
In the world of superbugs (bacteria that has grown resistant
FDA Approves Lonsurf (trifluridine/tipiracil) for Adult Patients with Previously Treated Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
PRINCETON, N.J., February 25, 2019 – Taiho Oncology, Inc. today
US opioid deaths jump fourfold in 20 years; epidemic shifts to Eastern states
Opioid-related deaths nationwide jumped fourfold in the last two decades,
CymaBay Therapeutics Announces Seladelpar Granted Breakthrough Therapy Designation by the FDA for the Treatment of Primary Biliary Cholangitis
NEWARK, Calif., Feb. 15, 2019 (GLOBE NEWSWIRE) — CymaBay Therapeutics,
Nano-painkiller lasts longer and is less addictive than opioids
A team of researchers from Université Paris-Saclay and Université Paris
FDA warns 17 companies about illegal Alzheimer disease products
(HealthDay)—A number of warning/advisory letters have been issued to 17
GPs and pharmacists don’t have time to involve patients in medication reviews
GPs and pharmacists struggle to find the time to involve